Abstract:Purpose China adopted its new Accounting Standards for Business Enterprises No. 6 in 2007, which substantially converges with the International Financial Reporting Standards. It stipulates that firms operating in China shall capitalize development costs provided specific criteria have been met. This paper aims to examine the effects of the new accounting policies of R&D on the value-relevance and stock performance of 36,299 Chinese firms-years from 2007 to 2020. Design/methodology/approach A comprehensive multi-stage analysis was conducted. Multiple linear regressions were performed on the pooled cross-sectional time-series total R&D, capitalized expenditures, expensed costs and other key financial factors to test for the effects of R&D on the stock prices, contemporaneous stock returns and subsequent stock returns for the full sample, capitalizer sample and expenser sample, respectively. Findings First, majority of Chinese firms (about 80% of those reported) elect to adopt expensing R&D approach, while about 20% deploys capitalization treatment. Second, key attributes such as size, profitability, leverage and R&D intensity are highly associated with capitalization propensity. Third, current capitalization affects the contemporaneous stock prices and stock returns (priced-in) with yearly volatility. Finally, intertemporal association exists between firms' expensing costs and subsequent returns due to a delayed reaction. Originality/value As the world largest emerging economy, the results show that research and development information adds value, and capitalizers outperforms expensers in the area of stock performance. This strategy works irrespectively of economic development stage or capital market maturity. The findings call for more capitalization.

Does R&D make stocks lottery-like?

Will R&D make investors more tolerant? Analysis based on the performance forecast of Chinese listed companies

R&D Investment Management and Ambidextrous Technological Innovation: Evidence from Chinese Listed Firms

R&D Expenditures, Ultimate Ownership and Future Performance: Evidence from China

Corporate Innovation and R&D Expenditure Disclosures

Impact of R&D innovation and political background on corporate growth: A study based on private listed companies in China

Research and development reporting and stock performance: evidence from China

Initial Public Offering, Corporate Innovation and Total Factor Productivity: Evidence from China

Corporate R&D and Stock Returns: International Evidence

The Research Between R&D Investment and Firm Value in the Resources Company

Independent Directors’ Status and R&D: a Study Based on Chinese Cultural Background

R&D Volatility and Market Value: the Role of Executive Overconfidence

Does Development of Financial Markets Help Firm Innovation? Evidence from China

Research on the Impact of Stock Price Volatility on Corporate R&D Investment

R&D Value of Chinese Manufacturing Listed Companies:on the Financial Market's Valuation of Corporate Assets

Investor Reaction to R&D Investment

Can fund shareholding inhibit insufficient R&D input?——Empirical evidence from Chinese listed companies

Financial Asset Allocations and R&D Activities: Evidence from China’s Listed Companies

Financial Asset Allocations and R&D Activities: Evidence from China's Listed Companies

Corporate social responsibility, financing capacity and innovation investment -- an empirical analysis based on a-share listed high tech enterprises

The impact of corporate R&D on the transformation of intellectual property into intangible assets